Enovis (ENOV) AI Stock Analysis

• Market Cap: $1.98B
• Dividend Yield: N/A
• Average Volume (3M): 1.50M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.23
• Revenue Growth: 18.32%
• EPS Growth: -712.12%
• Country: US
• Employees: 7,367
• Sector: Industrials
• Sector Strength: 89
• Industry: Industrial - Machinery
• EPS (TTM): 0.81
• Shares Outstanding: 57,123,050
• 10 Day Avg. Volume: 1,778,186
• 30 Day Avg. Volume: 1,503,225
• PEG Ratio: -1.05
• Price to Book (P/B): 0.75
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -50.90
• Enterprise Value/Market Cap: 1.72
• Enterprise Value/Revenue: 0.42
• Enterprise Value/Gross Profit: 3.01
• Enterprise Value/Ebitda: -3.29
• 1Y Price Target: $53.33
• Price Target Upside: 49.97% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10

• Rating: 45 Neutral
• Price Target: $33.00 ▼(-7.20%Downside)

Enovis faces significant financial challenges with consistent net losses and negative cash flow, heavily impacting its overall score. While the earnings call highlighted growth in key segments and successful product launches, tariff and currency challenges pose risks to margins. The technical analysis shows bearish momentum, and the valuation is unattractive with a negative P/E ratio.

Positive Factors

Financial Performance

The company is expected to show organic growth and margin expansion, further enhancing its financial performance.

Product Development

New products are ramping up, and some are already contributing to double-digit recon growth.

Valuation

Valuation is well below peers, making the stock very attractive for investors seeking potential growth.

Negative Factors

Guidance

Management raised their revenue guidance but lowered their EBITDA and EPS guidance to account for the impact of tariffs.

Price Target

The price target has been lowered to $70 from $75 by applying the same EV/Sales multiple in the last valuation update.

Tariffs

ENOV anticipates tariff impacts to its FY Adjusted EBITDA.

Enovis Business Overview & Revenue Model

Company Description

Enovis Corporation (ENOV) is a diversified medical technology company focused on developing innovative solutions in the field of healthcare. The company operates primarily in the medical technology sector, offering a range of products and services aimed at enhancing patient care and improving clinical outcomes. Enovis specializes in manufacturing and distributing advanced medical devices and equipment, particularly in the areas of orthopedic solutions, rehabilitation, and surgical technologies. Through its commitment to innovation and quality, Enovis serves a global customer base, including hospitals, clinics, and healthcare professionals.

How the Company Makes Money

Enovis Corporation generates revenue through the sale of its medical devices and equipment to healthcare providers, including hospitals, clinics, and rehabilitation centers. The company's key revenue streams include orthopedic products such as joint replacement systems, surgical tools, and rehabilitation equipment. Enovis also engages in strategic partnerships and collaborations with healthcare institutions and research organizations to expand its market presence and enhance its product offerings. Additionally, the company invests in research and development to drive innovation, which helps in maintaining a competitive edge and attracting a broad customer base. By focusing on high-quality, technologically advanced products, Enovis taps into the growing demand for medical technology solutions, thereby sustaining its revenue growth.

Enovis Financial Statement Overview

Summary

Enovis is facing significant financial challenges, primarily driven by operational inefficiencies resulting in consistent net losses and negative cash flow. Despite a healthy equity ratio and low leverage, the company struggles to convert revenue into profit, indicating a need for strategic changes to improve profitability and cash flow generation.

Income Statement

The income statement shows a concerning trend with declining revenues and consistent net losses. The TTM revenue growth is slow at 2.02%. Gross profit margins have remained strong at 52.62%, but the net profit margin is negative, indicating operational inefficiencies with a TTM net margin of -37.65%. The EBIT and EBITDA margins are also negative, reflecting significant operating challenges.

Balance Sheet

Enovis maintains a moderate debt-to-equity ratio of 0.03, showing effective management of debt. However, the return on equity is negative at -30.92% for TTM, signaling poor returns to shareholders. The equity ratio is strong at 53.69%, indicating a solid base of equity relative to total assets.

Cash Flow

The cash flow analysis reveals a struggle with free cash flow, which is negative and has decreased over time, with a TTM free cash flow of -$38.98 million. Despite positive operating cash flows of $148.06 million in TTM, the free cash flow to net income ratio remains unfavorable due to consistent net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.15B	2.11B	1.71B	1.56B	3.85B	3.07B
Gross Profit	1.13B	1.18B	990.78M	869.38M	1.61B	1.29B
EBITDA	-471.91M	-481.03M	169.92M	225.78M	95.03M	180.05M
Net Income	-809.46M	-825.49M	-33.26M	-38.19M	98.69M	64.08M
Balance Sheet
Total Assets	4.88B	4.72B	4.51B	4.27B	8.52B	7.35B
Cash, Cash Equivalents and Short-Term Investments	38.46M	48.17M	36.19M	24.30M	680.25M	97.07M
Total Debt	1.46B	1.40B	536.42M	310.54M	2.16B	2.37B
Total Liabilities	2.25B	2.15B	1.09B	823.45M	3.85B	3.76B
Stockholders Equity	2.62B	2.56B	3.42B	3.45B	4.62B	3.54B
Cash Flow
Free Cash Flow	-38.98M	-67.21M	12.77M	-161.31M	251.86M	187.15M
Operating Cash Flow	148.06M	113.50M	134.99M	-55.86M	356.10M	301.94M
Investing Cash Flow	-218.15M	-955.47M	-242.47M	-176.39M	-320.48M	-175.08M
Financing Cash Flow	33.47M	846.82M	127.80M	-465.13M	584.91M	-131.65M

Enovis Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 35.56
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENOV, the sentiment is Positive. The current price of 35.56 is above the 20-day moving average (MA) of 32.51, above the 50-day MA of 33.16, and below the 200-day MA of 39.75, indicating a neutral trend. The MACD of 0.60 indicates Negative momentum. The RSI at 65.30 is Neutral, neither overbought nor oversold. The STOCH value of 93.45 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ENOV.

Enovis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TNC	71 Outperform	$1.52B	22.74	11.04%	1.45%	1.35%	-40.63%
SXI	69 Neutral	$1.98B	32.45	9.29%	0.78%	2.67%	-18.41%
CXT	66 Neutral	$3.25B	19.53	16.23%	1.20%	9.28%	-8.45%
EPAC	64 Neutral	$2.05B	23.30	21.91%	0.10%	2.82%	7.50%
Sector *	58 Neutral	HK$13.95B	4.43	-3.01%	7.31%	3.67%	-54.16%
HI	50 Neutral	$1.60B	―	-18.22%	3.96%	0.31%	-423.59%
ENOV	45 Neutral	$1.98B	―	-27.40%	―	18.32%	-712.12%

Enovis Corporate Events

Enovis Holds Annual Meeting, Elects Board Directors

On May 21, 2025, Enovis Corporation held its Annual Meeting of Stockholders, where three proposals were presented. The stockholders elected nine directors to the board, ratified Ernst & Young LLP as the independent registered public accounting firm for 2025, and approved the executive compensation of the named executive officers.

The most recent analyst rating on (ENOV) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Enovis stock, see the ENOV Stock Forecast page.